Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
Chimerix (CMRX) will host a live conference call on November 4, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021, alongside an operational update. The call can be accessed via phone or through a live audio webcast available on the company's website. Notably, in June 2021, Chimerix received FDA approval for TEMBEXA, a treatment for smallpox. The company is also advancing ONC201, aimed at recurrent H3 K27M-mutant glioma, with efficacy results expected soon, and DSTAT, targeting acute myeloid leukemia.
- FDA approval granted for TEMBEXA for smallpox treatment.
- ONC201 is in a registrational clinical program with efficacy results expected in 2021.
- Risks identified regarding ONC201's Phase 2 clinical trial data may not support regulatory approval.
- Potential delays in securing a procurement contract for TEMBEXA.
DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their lives, today announced that it will host a live conference call and audio webcast on Thursday, November 4, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide an operational update.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 5935686. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their lives. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and the results from an efficacy analysis by blinded independent central review are expected in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s growth and development. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current Phase 2 clinical trial data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACTS:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
When will Chimerix announce its Q3 2021 financial results?
What significant drug approval did Chimerix receive recently?
What are the key clinical programs Chimerix is currently developing?
How can I access the Chimerix conference call?
